drugset / Trial / NCT02038829

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD

NCT02038829

Phase 2 Completed 96 enrolled Sunovion Respiratory Development Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.

Timeline

Start
2014-01
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aclidinium Small molecule 400 ug
Subject IVOSPEMIN Other / unclassified 3 ug Other
Subject IVOSPEMIN Other / unclassified 6.25 ug Other
Subject IVOSPEMIN Other / unclassified 12.5 ug Other
Subject IVOSPEMIN Other / unclassified 50 ug Other